A Phase 1b Dose Escalation and Dose Expansion Study of ONO/GS-4059 in Combination With Other Targeted Anti-cancer Therapies in Subjects With B-cell Malignancies

Trial Profile

A Phase 1b Dose Escalation and Dose Expansion Study of ONO/GS-4059 in Combination With Other Targeted Anti-cancer Therapies in Subjects With B-cell Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Tirabrutinib (Primary) ; Entospletinib; Idelalisib
  • Indications B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 28 Sep 2017 Planned End Date changed from 1 May 2020 to 1 Aug 2022.
    • 28 Sep 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2019.
    • 01 Sep 2017 Planned End Date changed from 1 Jul 2023 to 1 May 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top